Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + chidamide
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of ruxolitinib, a selective JAK1/JAK2 inhibitor, and chidamide (tucidinostat), a selective histone deacetylase (HDAC) inhibitor. This combination targets both the JAK-STAT signaling pathway and epigenetic regulation through HDAC inhibition. The combination has shown synergistic anti-tumor effects, particularly in overcoming chidamide resistance in Natural Killer/T-cell Lymphoma (NKTL) and potentially in other hematological malignancies.
02
Targets
HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)
Beyond the preview
Go deeper on ruxolitinib + chidamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + chidamide.